Survival of children with cancer in Italy, 1989-98. A report from the hospital based registry of the Italian Association of Paediatric Haematology and Oncology (AIEOP)

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Andrea PessionItalian Association of Paediatric Haematology and Oncology

Abstract

We describe the survival patterns of 10,791 Italian children (age 0-14) diagnosed with cancer during 1989-1998 and who were included in the hospital-based registry of the Italian Association of Paediatric Haematology and Oncology. Five-year cumulative survival percentages were 76% for lymphoproliferative disorders and 68% for solid tumours. Survival rates in 1994-1998 significantly improved for acute lymphocytic leukaemia (ALL), acute non-lymphocytic leukaemia, Hodgkin's lymphoma and Wilms' tumour. Gender and age were determinants of survival for some specific types of cancer. Girls with ALL and neuroblastoma exhibited a significant advantage (hazard ratio HR 0.72, 0.62-0.83) and disadvantage (HR 0.73, 0.59-0.90) over boys, respectively. Children with a Wilms' tumour diagnosed above age 3 had a worse prognosis than younger children (HR 2.3, 1.4-4.1). The persisting gender-related difference in survival rate for ALL requires understanding as to whether it is attributable to delays in the adoption of more recent therapeutic protocols, while the corresponding findings for Wilms' tumour and neuroblastoma deserve further biological interpretation.

References

Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A Stiller
Apr 29, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J CotterillJ Imeson
Apr 20, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W CoeberghUNKNOWN EUROCARE Working Group
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Pritchard-JonesUNKNOWN Wilm's Tumor Working Group
Dec 20, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GattaUNKNOWN EUROCARE Working Group
Jul 15, 2004·Blood·Ching-Hon PuiUNKNOWN Total Therapy Study XIIIB at St Jude Children's Research Hospital
Aug 19, 2005·Leukemia·A PessionUNKNOWN AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
Jan 18, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A GoubinJ Clavel
Aug 22, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W W CoeberghW A Kamps
Aug 22, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Claudia SpixEva Steliarova-Foucher
Aug 22, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Guido PastoreEva Steliarova-Foucher
Aug 22, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K Pritchard-JonesJ W W Coebergh
Sep 5, 2007·Haematologica·Iacopo BaussanoGuido Pastore
Dec 14, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emmanuel DesandesJacqueline Clavel

❮ Previous
Next ❯

Citations

Nov 26, 2010·Cancer Cell International·Thangarajan RajkumarSeshadri A Ramakrishnan
Jan 14, 2011·Haematologica·Emanuele PivettaUNKNOWN Italian Association of Pediatric Hematology and Oncology (AIEOP) Group
Mar 4, 2009·Dermatologic Clinics·Luigi Naldi, Liliane Chatenoud
Aug 30, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elisa DamaUNKNOWN Italian Association of Pediatric Hematology and Oncology (AIEOP)
Jul 17, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Norbert GrafJan de Kraker
Jan 13, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Andrea FerrariGuido Pastore
May 15, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Paraskevi PapathomaEleni Th Petridou
Jul 25, 2019·Italian Journal of Pediatrics·Momcilo JankovicFranca Benini
Sep 8, 2016·Italian Journal of Pediatrics·Paolo IndolfiFiorina Casale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.